p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
复制标题
DOI：
10.1158/1055-9965.epi-09-0880
复制
发表时间：
2010-03
期刊：
影响因子：
--
通讯作者：
Cramer D
中科院分区：
文献类型：
--
作者：
Anderson KS;Wong J;Vitonis A;Crum CP;Sluss PM;Labaer J;Cramer D
本研究探讨了血清p53自身抗体（p53-AAb）作为卵巢癌检测和预后生物标志物的价值。通过ELISA检测术前从接受盆腔肿块手术的妇女获得的血清中的p53-AAb。该组包括随后诊断为浸润性浆液性卵巢癌（N=60）、非浆液性卵巢癌（N=30）和良性疾病（N=30）的女性。从一般人群中选择了符合条件的对照组（N=120）。构建受试者工作特征曲线以比较作为筛选生物标志物的p53-AAb、CA 125和HE 4的值。Kaplan-Meier曲线和考克斯比例风险模型用于评估其对生存的预后价值。在25/60（41.7%）浆液性病例、4/30（13.3%）非浆液性病例、3/30（10%）良性疾病病例和10/120（8.3%）对照中检测到p53-AAb（合并p=0.0002）。与CA 125（AUC = 0.99）或HE 4（AUC=0.98）相比，p53-AAb没有显著改善病例的检测（AUC = 0.69）或良性与恶性疾病的区分（AUC =0.64）。在多变量分析中，p53-AAb仅与乳腺癌家族史相关（p=0.01）。治疗前血清中可检测到的p53抗体与浆液性卵巢癌总生存率的改善相关（p=0.04，HR=0.57（95%CI =0.33，0.97））。在42%的晚期浆液性卵巢癌患者的血清中检测到p53抗体。尽管它们作为除CA 125和HE 4之外的术前诊断生物标志物的实用性有限，但它们对于改善总生存率具有预后作用。
This study examined the value of serum p53 autoantibodies (p53-AAb) as detection and prognostic biomarkers in ovarian cancer. p53-AAb were detected by ELISA in sera obtained pre-operatively from women undergoing surgery for a pelvic mass. This group included women subsequently diagnosed with invasive serous ovarian cancer (N=60), non-serous ovarian cancers (N=30), and women with benign disease (N=30). Age-matched controls were selected from the general population (N=120). Receiver operating characteristic curves were constructed to compare the values of p53-AAb, CA 125, and HE4 as a screening biomarker. Kaplan-Meier curves and Cox proportional hazards modeling were used to assess its prognostic value on survival. p53-AAb were detected in 25/60 (41.7%) of serous cases, 4/30 (13.3%) non-serous cases, 3/30 (10%) benign disease cases, and 10/120 (8.3%) controls (combined p=0.0002). p53-AAb did not significantly improve detection of cases (AUC=0.69) or discrimination of benign versus malignant disease (AUC=0.64) compared with CA 125 (AUC=0.99) or HE4 (AUC=0.98). In multivariate analysis among cases, p53-AAb correlated only with a family history of breast cancer (p=0.01). Detectable p53 antibodies in pre-treatment sera were correlated with improved overall survival (p=0.04, HR=0.57 (95% CI=0.33, 0.97)) in serous ovarian cancer. Antibodies to p53 are detected in the sera of 42% of patients with advanced serous ovarian cancer. Although their utility as a pre-operative diagnostic biomarker, beyond CA 125 and HE4, is limited, they are prognostic for improved overall survival.